No. Placental tissue and umbilical cord tissue are different sources, although both can provide mesenchymal stromal cells (MSCs). Placental MSCs may be fetal or maternal, depending on the layer; cord-tissue MSCs are fetal in origin. Sharing the MSC label does not make two products interchangeable. A direct laboratory comparison found fetal MSCs in the umbilical cord, amniotic membrane and chorionic plate, but maternal MSCs in the decidua S41598 018 23396 1.
Cord blood is a separate category. It contains blood-forming, or hematopoietic, stem and progenitor cells used in transplantation. That is not the same treatment as an injection of placental or Wharton’s jelly MSCs Stem cell transplant. Before comparing benefits or risks, establish whether “cord cells” means cord tissue or cord blood.

Placental cells versus cord cells
The placenta has fetal and maternal components. In the 2018 comparison, MSCs isolated from the amnion and chorionic plate were fetal, while those from decidua parietalis were maternal. Researchers established origin using human leukocyte antigen (HLA) typing and chromosome analysis; a tissue label alone is not a batch test S41598 018 23396 1.
The umbilical cord contains Wharton’s jelly, a connective tissue surrounding its blood vessels, as well as cord lining and perivascular tissue. These are tissue sources, distinct from the blood inside the vessels. Isolation and culture methods affect which cell populations a laboratory obtains 25622293.
| Label | Starting material | Cell identity | What to clarify |
|---|---|---|---|
| Amnion or chorionic-plate MSCs | Fetal placental layers | Fetal MSCs in the laboratory comparison | Exact layer and isolation method S41598 018 23396 1 |
| Decidual MSCs | Maternal placental tissue | Maternal MSCs; mixed-origin cultures can occur | Evidence of cell origin and purity S41598 018 23396 1 |
| Wharton’s jelly MSCs | Connective tissue within the cord | Cord-tissue MSCs | Living expanded cells versus processed tissue 25622293 |
| Cord-lining or perivascular cells | Other cord-tissue compartments | Cell populations depend on isolation | Do not assume they match a Wharton’s jelly product 25622293 |
| Cord blood cells | Blood collected from the cord after birth | Blood-forming stem and progenitor cells | Transplant indication and donor suitability Stem cell transplant |
Why both can be called MSCs
The 2006 International Society for Cellular Therapy criteria describe laboratory characteristics, not a treatment indication. MSCs must adhere to plastic in standard culture, express CD105, CD73 and CD90, lack CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR, and differentiate into bone, fat and cartilage cells in vitro 14653240600855905.
Cells from different placental and cord compartments can share these characteristics while differing in growth and signaling. In the 2018 comparison, fetal MSCs expanded faster than maternal MSCs, and the sources released different levels of selected signaling factors S41598 018 23396 1. These findings do not show that one source repairs human tissue better.
A separate study using tissue from 17 healthy full-term placentas reported 390 cord-specific differentially expressed genes and 247 downregulated placenta-specific genes in its expression analysis. These are differences in gene activity, not extra genes present in one source or proof of superior treatment J.tjog.2017.08.016.
Why cord blood is not a substitute
Blood-forming stem cell transplantation uses cells from peripheral blood, bone marrow or cord blood. It is used for selected blood cancers and other blood disorders; the choice of source depends on the disease and transplant plan. A general list of transplant indications should not be read as a list for which cord blood is always the preferred source Stem cell transplant.
The cells are infused through a vein after conditioning with chemotherapy, sometimes with radiation. Donor transplants carry graft-versus-host disease risk, and immune recovery can take one to two years. Placental or cord-tissue MSC injections do not replace the blood-forming graft Stem cell transplant.
In the United States, the FDA warns about unapproved regenerative products, including those marketed using cord blood, amniotic fluid or Wharton’s jelly. Its warning describes infections, unwanted immune responses, blindness, tumors and unintended tissue growth. It does not mean every tissue-derived product has the same regulatory status or risk Important patient and consumer information about regenerative medicine therapies.
Does either source work better?
The studies below cannot rank placental versus cord MSCs: they concern different products, diseases and delivery routes. None is a direct placental-versus-cord clinical comparison.
An approval for a different MSC source
In December 2024, the FDA approved Ryoncil, a donor bone-marrow MSC product, for steroid-refractory acute graft-versus-host disease in children aged two months and older. In its single-arm study of 54 children, the initial course comprised eight intravenous infusions over four weeks. At day 28, 30% had a complete response and 41% a partial response. Common adverse reactions included infections, fever, bleeding, swelling, abdominal pain and high blood pressure; warnings include infusion reactions, infection transmission and ectopic tissue formation. This approval does not extend to placental or cord MSC products Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host.
Placental-derived cells in PACE
PACE was a phase III randomized trial of PLX-PAD, a placental-derived MSC-like product, at 42 sites in the United States and Europe. It enrolled 213 adults with chronic limb-threatening ischemia and minor tissue loss who were unsuitable for revascularization: 143 were assigned PLX-PAD and 70 placebo. The protocol specified 30 intramuscular injections of 0.5 mL into the affected leg on day 0 and another 30 on day 60, with planned follow-up of 12–36 months PMC10828925.
The primary endpoint was amputation-free survival. The reported probability of major amputation or death was 28.6% with PLX-PAD and 33% with placebo during study follow-up; the adjusted hazard ratio (HR) was 0.93 (95% confidence interval 0.53–1.63; P = 0.788). The trial stopped early for futility and did not meet its primary endpoint PMC10828925.
A post hoc subgroup of 121 patients with baseline HbA1c below 6.5% had a favorable 12-month result (HR 0.46, 95% CI 0.21–0.99; P = 0.048). At 36 months, the result was not statistically significant (HR 0.60, 95% CI 0.30–1.21; P = 0.151). That does not prove the effect disappeared; the exploratory finding needs confirmation. In the safety population (136 PLX-PAD recipients and 69 placebo recipients), adverse events after dosing occurred in 73.5% and 82.6%, respectively, often reflecting the underlying limb disease. Injection-site reactions occurred in 12.5% and 10.1%, respectively PMC10828925.
Cord-tissue MSCs for knee disease
A 2025 systematic review of intra-articular umbilical-cord/Wharton’s jelly MSCs for knee osteoarthritis and cartilage injury included six studies, 97 patients and 134 knees. Two studies were randomized and four were not; doses and injection schedules differed. Follow-up ranged from 3 to 48 months, although most study periods were under a year. Pain and function measures generally improved, but not every comparison was statistically significant, and imaging findings were mixed PMC11942840.
No serious adverse effects were reported in those studies, but knee effusion and pain occurred. Small studies cannot establish long-term safety or prove cartilage regrowth. These knee results cannot be compared directly with PACE’s limb-ischemia results or used as evidence that cord MSCs outperform placental MSCs PMC11942840. A page about knee joint disorders is also not evidence for a particular cell preparation.
Is one source safer?
The evidence above does not establish a safer source. “Immune-privileged” should not be read as “immune-risk-free.” For a proposed donor-cell treatment, ask about donor screening, sterility, cell identity, viability, potency testing and monitoring. The FDA warns that unapproved cell products can cause unwanted inflammatory or immune responses and contamination-related infections Important patient and consumer information about regenerative medicine therapies.
Placental extracts also must not be equated with living, culture-expanded MSCs. In a May 2026 warning, the FDA described a reported death after self-injection of an unapproved imported placental tissue-derived product. The administered product could not be tested, and testing of remaining samples did not isolate the pathogen associated with the death. This report does not establish causation or quantify the risk of all placental products Patient and consumer warning about potential serious risks harm following use unapproved products.
What to check in a Japanese offer
Japan’s Act on the Safety of Regenerative Medicine (ASRM) covers research and clinical provision of cell therapies, while the Pharmaceuticals and Medical Devices Act governs commercialization of regenerative medical products. Both frameworks took effect in November 2014. An ASRM provision plan is not product marketing approval or evidence that treatment works for a disease 0003.
Provision plans can be searched in the MHLW public database, but a published entry does not establish efficacy 2. The distinction between these routes also matters when reading a registration and compliance explanation.
For example, if a written offer says only “cord cells, intravenous infusion,” it does not identify whether the material is cord blood or a cord-tissue preparation. A knee study using injections into the joint would not, by itself, support an intravenous product. Ask for the preparation and route to be matched to the cited study before treating it as relevant evidence.
When checking a clinic in Japan, request:
- The exact tissue compartment and cell type, not just “placental” or “cord.”
- Fetal or maternal origin, and donor-derived or your own cells; these are separate questions. The autologous versus allogeneic distinction concerns whose cells are used.
- Whether the preparation contains living cells or an extract, with cell count, viability, passage number and release-test results where applicable.
- A human study matching the product, diagnosis, dose and route, including control group, outcomes, follow-up and adverse events.
- The applicable approval, provision-plan or clinical-trial record, checked independently rather than treated as an efficacy certificate.
- Expected risks, emergency arrangements and a written follow-up plan.
Bottom line
Placental MSCs, cord-tissue MSCs and cord-blood stem cells are not interchangeable labels. Shared laboratory markers do not establish equal clinical effects, and the studies discussed here do not show that one MSC source is better than the other. Compare the exact preparation and evidence for your condition with a qualified treating specialist, rather than choosing on tissue name alone.
Comparing a placental or cord-cell offer in Japan? Bring the exact tissue, the study behind it, and the plan number to your inquiry.
This information explains cell sources and published evidence; it is not an individual treatment recommendation. Sources were reviewed on 23 and 28 October 2026. Approval and availability must be checked for the exact product, indication and country.




